

March 17, 2025
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Appointment of Senior Vice President, Head of R&D of SymBio Pharma USA, Inc.

TOKYO, March 17, 2025 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, hereinafter “SymBio”) today announced that effective March 17, 2025, Dr. Edwin Rock, MD, PhD, (hereinafter “Dr. Rock”) will join SymBio Pharma USA, Inc. (hereinafter “SPU”) as Senior Vice President, and Head of R&D (hereinafter “Head of R&D”). SPU was established in May 2016 as a wholly owned U.S. subsidiary of SymBio Pharmaceuticals Limited.

Dr. Rock received M.D. and PhD degrees from Stanford University School of Medicine in the United States, held several research positions, and served as a medical officer to the Food and Drug Administration before his employment by major pharmaceutical companies in global drug development. He has extensive medical, regulatory, scientific, and clinical experience, including as chief medical officer at his two most recent positions.

To further strengthen our global development organization, we welcome Dr. Rock, who will accelerate BCV development, optimize regulatory strategy, and drive its commercialization, thereby supporting our steady growth as a global specialty pharmaceutical company.

Statement from Dr. Edwin Rock: “I am excited to join the SymBio Pharma USA management team as Head of R&D. BCV has potential to be an effective treatment for infectious diseases caused by double-stranded DNA viruses, as well as for multiple malignancies and neurodegenerative diseases.

I look forward to working together with the SymBio team to bring new drugs as soon as possible to patients with intractable diseases for which currently there are no effective treatments.”

Statement from Fuminori Yoshida, President and CEO of SymBio: “I am pleased to welcome Dr. Rock, who has outstanding knowledge of the global development business and a proven track record of developing numerous new drugs, to our management team. This hire will further strengthen our development infrastructure to achieve a global specialty pharmaceutical company.”

[Contact]

Investor Relations Tel: +81(0)3 5472 1125

1. Appointment of Senior Vice President, Head of R&D of SymBio Pharma USA, Inc.

Name	Title
Edwin Rock	Senior Vice President, Head of R&D

2. Date of appointment: March 17, 2025

3. Profile

2001	Vice President, Leerink Swann and Company
2004	Medical Officer, Office of Oncology Drug Product, Food and Drug Administration
2007	Medical Director, GlaxoSmithKline R&D
2009	Sr. Director, Global Clinical Dev., Otsuka Pharmaceutical Dev. & Commercialization, Inc.
2016	Executive Director, Clinical Research, Astex Pharmaceuticals, Inc. (Ohtsuka Group)
2017	Vice President, Clinical Research, MacroGenics, Inc.
2020	Chief Medical Officer, Partner Therapeutics, Inc.
2022	Chief Medical Officer (SVP), GlycoMimetics, Inc.
1978	B.A. Swarthmore College
1986	Ph.D. Stanford University School of Medicine
1991	M.D. (Doctor of Medicine) Stanford University School of Medicine
1998	Medical Resident, Brigham and Women's Hospital
2002	Medical Oncology Fellow, University of Pennsylvania

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.